KRTX News and Press, Karuna Therapeutics Inc. From 08/08/22

Karuna Therapeutics (NASDAQ: KRTX) , a clinical-stage biotech , is having a record-breaking day. As of 2:25 p.m. ET, the company's shares were up by an eye-popping 70%, surging to an all-time high during Monday's trading session. Although the biotech released its 2022 second...

Neurocrine saw a meaningful improvement in Ingrezza sales, with revenue growing 32% and beating sell-side expectations by 8%. Management announced that '104 failed to show meaningful efficacy in a Phase II proof-of-concept study, and the company has few near-term clinical catalysts. ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Bukhta Yurii / Shutterstock.com Karuna Therapeutics (NASDAQ: KRTX ) stock is rocketing higher on Monday thanks to results from its Phase 3 EMERGENT-2 trial . This trial covers the efficacy, safety, an...

Gainers: CinCor Pharma CINC +66% . Karuna Therapeutics KRTX +61% . 23andMe ( ME ) +22% . Cerevel Therapeutics ( CERE ) +20% . Quoin Pharmaceuticals ( QNRX ) +16% . Losers: Reata Pharmaceuticals RETA -31% . uniQure QUR...

The shares of Karuna Therapeutics ( NASDAQ: KRTX ) surged ~52% in the pre-market on Monday after the clinical-stage biotech announced that its late-stage trial for experimental schizophrenia therapy KarXT met the primary endpoint. The ADRs of Chinese biotech Zai Lab Limited ...

The shares of Karuna Therapeutics ( NASDAQ: KRTX ) surged ~38% in the pre-market on Monday after the clinical-stage biotech announced that its late-stage trial for experimental schizophrenia therapy KarXT met the primary endpoint. The Phase 3 trial named EMERGENT-2 invol...

Trial met primary endpoint, with KarXT demonstrating a statistically significant 9.6-point reduction in PANSS Total Score compared to placebo at Week 5 (p<0.0001) Trial also met key secondary endpoints, demonstrating statistically significant reductions in positive and negative...

Karuna Therapeutics press release ( NASDAQ: KRTX ): Q2 GAAP EPS of -$2.17 misses by $0.10 . Revenue of $5.28M. The Company ended the quarter with $407.4 million in cash, cash equivalents and available-for-sale investment securities compared to $494.0 million as o...

Met primary and key secondary endpoints in Phase 3 EMERGENT-2 trial of KarXT in schizophrenia The Company plans to submit a New Drug Application (NDA) with the U.S. Food & Drug Administration (FDA) in mid-2023 Topline data from the Phase 3 EMERGENT-3 trial and ...

Trial met primary endpoint, with KarXT demonstrating a statistically significant 9.6-point reduction in PANSS Total Score compared to placebo at Week 5 (p<0.0001) Trial also met key secondary endpoints, demonstrating statistically significant reductions in positive and nega...